NJ-LTIMINDTREE
4.3.2024 14:16:28 CET | Business Wire | Press release
Fosfor, a product division of LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, at its Foton 2024 event, announced the launch of the Fosfor Decision Cloud (FDC). The FDC is a connected fabric that helps companies organize data to build automated, modular, trustworthy data transformation pipelines, build and deploy impactful AI applications, and harness the power of AI to make better business decisions, faster.
Currently companies need to create their own collection of disconnected point solutions to facilitate the transformation of data into business insights. The Decision Cloud represents the next step in the evolution of formerly disconnected data and AI investments into a modern decision stack that augments the data-to-decisions journey using three new innovations:
- Fosfor AI: The GenAI-powered assistant that helps with frequent tasks across the data-to-decisions journey such as constructing data pipelines, generating ML model code, constructing natural language prompts, and curating data stories. Fosfor AI radically increases productivity for virtually any user persona, thereby reducing time-to-insights and accelerating the realization of business outcomes.
- Fosfor Semantic: The knowledge graph used by all FDC capabilities to organize and maintain the integrity of data, define data relationships, and enable the application of advanced analytics to the data. Because Fosfor Semantic is used to facilitate everything from data integration to AI algorithm development to insight generation, it vastly accelerates all steps of the data-to-decisions journey.
- Fosfor UX: The design system through which all capabilities are accessed using consistent navigational elements and constructs, curated for specific personas based on their commonly used workflows and goals. Fosfor UX flattens the learning curve and simplifies collaboration across various personas, allowing all users to adapt more quickly to the FDC platform.
The FDC is supported by a robust partner ecosystem anchored by Snowflake, Fivetran, Amazon Web Services, Microsoft Azure, the Google Cloud Platform, and GoldenSource. Snowflake, the Data Cloud company, and Fivetran are FDC launch partners.
“The Decision Cloud marks a major milestone in the evolution of Fosfor and is a major breakthrough in the way businesses can develop and deploy AI to achieve business value,” said Debasis Satpathy, Chief Business Officer, Fosfor. “To elevate the impact of business outcomes, the Decision Cloud brings all the required capabilities onto a single platform, along with powerful insight tools, to support every persona involved in an accelerated data-to-decisions journey. We are excited about the impact the FDC is going to have on the business effectiveness of AI.”
"Organizations across industries continue to struggle with the fragmentation of applications and tools,” said Tarik Dwiek, Head of Technology Alliances, Snowflake. “With the Fosfor Decision Cloud seamlessly integrated into Snowflake, customers can now tap into a single experience to fully democratize their data and fuel their data-driven decision making.”
“Fivetran is pleased to be Fosfor’s launch partner for automated data movement,” said Scott Jones, Chief Revenue Officer, Fivetran. “Providing the foundational capability to integrate with virtually any data source to cost-effectively bring business data into cloud warehouses where the Decision Cloud can then transform it into insights and business value. Using our library of 400+ connectors, Decision Cloud users can focus on building outcome-targeted data products that accelerate their insights journey. We look forward to working together with Fosfor to define the modern decision stack and create transformational outcomes for our customers.”
Learn more about the Fosfor Decision Cloud at www.fosfor.com.
About Fosfor
The Fosfor Decision Cloud is a connected fabric that unifies and amplifies the value promised by the modern data ecosystem, which is made up of infrastructure, data, and application clouds. Fosfor enables organizations to effectively curate data, generate impactful insights, and formulate effective decisions to deliver the long-sought promise of data and AI: optimal business outcomes. Fosfor is part of LTIMindtree, a global technology consulting and digital solutions company. For more information, visit www.fosfor.com.
About LTIMindtree
LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 82,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — combines the industry-acclaimed strengths of erstwhile Larsen and Toubro Infotech and Mindtree in solving the most complex business challenges and delivering transformation at scale. For more information, please visit https://www.ltimindtree.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240304342757/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom